Ignite Creation Date:
2024-10-25 @ 7:48 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06527365
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-25
Brief Title:
Safety and Efficacy of VDPHL01 in Males With AGA
Sponsor:
None
Organization:
None
Study Overview
Official Title:
An Open-Label Multi-Dose Study to Evaluate the Safety and Efficacy of VDPHL01 in Male Subjects With Androgenetic Alopecia
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia AGA
AGA or male pattern baldness is a genetic disorder caused by an excessive too much hair follicle response to androgens hormone that causes hair loss VDPHL01 85 mg Tablet is an investigational oral drug to treat male pattern baldness
This single center open-label study will last about 6 months and includes 7 study visits screening baseline day 1 week 2 month 1 month 2 month 4 month 6 Male subjects that meet the study eligibility criteria will be administered VDPHL01 twice daily for 6 months
AGA or male pattern baldness is a genetic disorder caused by an excessive too much hair follicle response to androgens hormone that causes hair loss VDPHL01 85 mg Tablet is an investigational oral drug to treat male pattern baldness
This single center open-label study will last about 6 months and includes 7 study visits screening baseline day 1 week 2 month 1 month 2 month 4 month 6 Male subjects that meet the study eligibility criteria will be administered VDPHL01 twice daily for 6 months
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None